CN102711825A - 用于施用EpCAMxCD3双特异性抗体的给药方案 - Google Patents

用于施用EpCAMxCD3双特异性抗体的给药方案 Download PDF

Info

Publication number
CN102711825A
CN102711825A CN2010800523771A CN201080052377A CN102711825A CN 102711825 A CN102711825 A CN 102711825A CN 2010800523771 A CN2010800523771 A CN 2010800523771A CN 201080052377 A CN201080052377 A CN 201080052377A CN 102711825 A CN102711825 A CN 102711825A
Authority
CN
China
Prior art keywords
bispecific antibody
dose
epcamxcd3 bispecific
period
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800523771A
Other languages
English (en)
Chinese (zh)
Inventor
格哈德·祖格梅尔
彼得·库福尔
多米尼克·鲁丁格尔
萨宾·考比特苏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Micromet GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet GmbH filed Critical Micromet GmbH
Publication of CN102711825A publication Critical patent/CN102711825A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2010800523771A 2009-09-18 2010-09-20 用于施用EpCAMxCD3双特异性抗体的给药方案 Pending CN102711825A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US24365109P 2009-09-18 2009-09-18
EP09170715 2009-09-18
EP09170715.8 2009-09-18
US61/243,651 2009-09-18
US34414710P 2010-06-01 2010-06-01
EP10164596 2010-06-01
US61/344,147 2010-06-01
EP10164596.8 2010-06-01
PCT/EP2010/063795 WO2011033105A1 (en) 2009-09-18 2010-09-20 Dosage regimen for administering an epcamxcd3 bispecific antibody

Publications (1)

Publication Number Publication Date
CN102711825A true CN102711825A (zh) 2012-10-03

Family

ID=43127167

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800523771A Pending CN102711825A (zh) 2009-09-18 2010-09-20 用于施用EpCAMxCD3双特异性抗体的给药方案

Country Status (15)

Country Link
US (1) US20120244161A1 (enExample)
EP (1) EP2477653A1 (enExample)
JP (1) JP2013505223A (enExample)
KR (1) KR20120083359A (enExample)
CN (1) CN102711825A (enExample)
AU (1) AU2010297258A1 (enExample)
BR (1) BR112012008345A2 (enExample)
CA (1) CA2774732A1 (enExample)
IL (1) IL218637A0 (enExample)
IN (1) IN2012DN03172A (enExample)
MX (1) MX2012003175A (enExample)
NZ (1) NZ598601A (enExample)
RU (1) RU2012115480A (enExample)
SG (2) SG10201405434VA (enExample)
WO (1) WO2011033105A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135968A (zh) * 2015-08-28 2018-06-08 阿穆尼克斯运营公司 嵌合多肽组装体及其制备和使用方法
CN108602891A (zh) * 2016-03-30 2018-09-28 霍斯特·林德霍费尔 治疗尿道恶性肿瘤的多特异性抗体
CN111356700A (zh) * 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
CN112807429A (zh) * 2015-11-19 2021-05-18 雷维托普有限公司 用于对非所要细胞进行重定向杀灭的两组分系统的功能性抗体片段互补作用
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
WO2013083809A1 (en) 2011-12-09 2013-06-13 Amgen Research (Munich) Gmbh Prevention of adverse effects caused by epcamxcd3 bispecific antibodies
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
RS64664B1 (sr) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
ES3012974T3 (en) * 2014-01-08 2025-04-10 Univ Leland Stanford Junior Targeted therapy for lung cancer
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
PH12018501628B1 (en) 2016-02-01 2023-11-10 Bioverativ Therapeutics Inc Optimized factor viii genes
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
EP3409322A1 (en) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN114390938B (zh) 2019-03-05 2025-03-21 武田药品工业有限公司 受约束的条件性活化的结合蛋白
CN115279896A (zh) 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 慢病毒载体配制品
IL299333A (en) 2020-06-24 2023-02-01 Bioverativ Therapeutics Inc Methods for the purification of viral vectors
US20250002605A1 (en) * 2021-11-19 2025-01-02 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
HRP20110187T1 (hr) 2003-10-16 2011-04-30 Micromet Ag Multispecifične deimunizirane tvari koje vežu cd3
DK1874821T3 (da) * 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KLAUS BRISCHWEIN,ET AL: "MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors", 《MOLECULAR IMMUNOLOGY》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135968A (zh) * 2015-08-28 2018-06-08 阿穆尼克斯运营公司 嵌合多肽组装体及其制备和使用方法
CN112807429A (zh) * 2015-11-19 2021-05-18 雷维托普有限公司 用于对非所要细胞进行重定向杀灭的两组分系统的功能性抗体片段互补作用
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN108602891A (zh) * 2016-03-30 2018-09-28 霍斯特·林德霍费尔 治疗尿道恶性肿瘤的多特异性抗体
CN111356700A (zh) * 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
US11744892B2 (en) 2017-09-08 2023-09-05 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
US11744893B2 (en) 2017-09-08 2023-09-05 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
US12478673B2 (en) 2017-09-08 2025-11-25 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins

Also Published As

Publication number Publication date
IN2012DN03172A (enExample) 2015-09-25
SG10201405434VA (en) 2014-10-30
MX2012003175A (es) 2012-04-11
US20120244161A1 (en) 2012-09-27
RU2012115480A (ru) 2013-10-27
JP2013505223A (ja) 2013-02-14
WO2011033105A1 (en) 2011-03-24
BR112012008345A2 (pt) 2016-08-09
KR20120083359A (ko) 2012-07-25
CA2774732A1 (en) 2011-03-24
IL218637A0 (en) 2012-05-31
NZ598601A (en) 2014-05-30
AU2010297258A1 (en) 2012-03-29
EP2477653A1 (en) 2012-07-25
SG179027A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
CN102711825A (zh) 用于施用EpCAMxCD3双特异性抗体的给药方案
WO2018213297A1 (en) Treatment of cancer with anti-gitr agonist antibodies
WO2021228178A1 (en) Compositions and methods for treating cancer
US20220372161A1 (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
WO2020211804A1 (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
CN111655725A (zh) 用于治疗癌症的组合产品
US20240109972A1 (en) Antibody and taxane combination therapy
CN118632872A (zh) 用于治疗癌症的组合疗法
TWI814752B (zh) 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途
RU2833461C1 (ru) Способы лечения рака шейки матки путем введения инибитора pd-1
KR20250075750A (ko) 항-ctla4 항체를 사용한 암의 치료 방법
HK40112915A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
EP4392068A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
WO2024097896A1 (en) Methods for treating cancer using anti-ctla4 antibody in combination with pembrolizumab
CN118251234A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
CN120437318A (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
JP2025542297A (ja) 肺癌の組み合わせ療法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Munich, Germany

Applicant after: Amgen Research Munich GmbH

Address before: Munich, Germany

Applicant before: Micromet AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: MICROMET AG TO: AMGEN RESEARCH MUNICH GMBH

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121003